News & Media

5 August 2025

N2CR had its 3rd annual retreat at Grand Copthorne Waterfront Hotel on 25 July 2025. From inspiring discussions and exch...

21 July 2025

A Phase I clinical trial, led by N2CR clinician-scientist A/Prof David Tan, tested a new drug combination—Selinexor, n...

20 June 2025

Multiple myeloma (MM) is a type of blood cancer that originates from abnormal plasma cells in the bone marrow, leading t...

9 April 2025

Multiple primary cancers (MPC) often indicate a hereditary cancer predisposition syndrome. In a study led by Prof Lee So...

13 March 2025

Chronic lymphocytic leukemia (CLL) is a type of cancer that affects the blood and bone marrow, leading to the buildup of...

28 February 2025

Muscle is our first line of defence against cancer. A randomised clinical trial in Singapore, led by N2CR members A/Prof...

23 February 2025

Nasopharyngeal carcinoma (NPC) is common in South China and parts of Southeast Asia. Despite treatment, 20-30% of patien...

21 January 2025

A study led by Dr Alan Prem Kumar, a member of N2CR, delves into how cancer arises from disruptions in cell cycle regula...

17 January 2025

Gastric cancer (GC) has significant global mortality with high heterogeneity. A study of 226 GC samples from 121 patient...